OXBRYTA's market potential is driven by its novel mechanism targeting HbS polymerization in sickle cell disease, leading to strong hemoglobin improvements. Its convenient oral, once-daily dosing ...

EMPAVELI's key market opportunities include its strong differentiation through C3 inhibition, capturing PNH patients inadequately controlled by C5 inhibitors. Expansion into rare kidney diseases, ...

Agios Pharmaceuticals has submitted a supplemental New Drug Application to the FDA seeking accelerated approval of mitapivat ...

FAQs on Preventive Care and Bodily Autonomy. The recent Supreme Court decision temporarily preserved nationwide access ...

Have you ever considered iron deficiency to be the cause of your hair fall If not it is time to get yourself checked for iron ...

The ex vivo therapies from BRL Medicine and Reforgene Medicine use different strategies to boost production of fetal hemoglobin.

These health tests can help you and your doctor make treatment and lifestyle decisions for a better, longer retirement.

Former University of Wyoming star linebacker Chad Muma was 13 years old when he was diagnosed as diabetic. The first thing he ...

MedX Health Corp. (" MedX " or the " Company ") (TSX-V: MDX) is pleased to announce that, further to its Press Release dated April 15, 2026, when it announced application for an extension of time ...